Biosimilar Competition. If, in a particular country, a Third Party obtains approval for and sells a Biosimilar Product with respect to a particular Product and achieves Biosimilar Competition in such country with respect to such Product, then the Net Sales for such Product in such country will be reduced by for the remainder of the Royalty Term for such Product in such country, subject to Section 5.5.4 (Mechanics of Adjustment to Royalties).
Biosimilar Competition. If during any Calendar Quarter during the Royalty Period for a Product in a given country, and such Product sold in such Calendar Quarter in such country (as determined by data obtained from a mutually agreed upon Third Party source), then the percentage royalty payable on Net Sales of such Product in such country will be reduced by for such Calendar Quarter.
Royalty Reduction Due to Biosimilar Competition. Subject to [Section 7.6.6], on a Licensed Product-by-Licensed Product and country-by-country basis, if during any during the Royalty Term for such Licensed Product in such country there are or more Biosimilar Products being sold in such country with respect to such Licensed Product, then the royalty rates used to calculate royalties due on Net Sales of such Licensed Product in such country for such shall be reduced from the royalty rates set forth in [Section 7.6.1] as follows:
AllDrafts is a cloud-based editor designed specifically for contracts. With automatic formatting, a massive clause library, smart redaction, and insanely easy templates, it’s a welcome change from Word.
And AllDrafts generates clean Word and PDF files from any draft.